OrbiMed’s Carisma Therapeutics CARM Stock Holding History

OrbiMed’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-36,580	Closed	-$2.06M	–	136
2015 Q2	$2.06M	Buy	+36,580	New	+$5.16M	0.02%	129

Other funds holding CARM

TRV

Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OrbiMed's CARM Position: Q3 2015 in Review

OrbiMed sold out of Carisma Therapeutics (CARM) in Q3 2015, closing a stake of 36,580 shares — an estimated $2.06M sold.

OrbiMed first reported a position in CARM in Q2 2015 and held it in 1 quarter. The position peaked at $2.06M in Q2 2015. 30 funds tracked by Wall St. Rank hold CARM as of Q3 2015.

OrbiMed reported no remaining Carisma Therapeutics position as of Q3 2015 after selling out during the quarter.
OrbiMed sold 36,580 Carisma Therapeutics shares in Q3 2015, an estimated $2.06M.
OrbiMed first reported a position in Carisma Therapeutics in Q2 2015 and held it in 1 quarter.
OrbiMed's Carisma Therapeutics position peaked at $2.06M in Q2 2015.
30 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2015.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.